Chimeric antigen receptor T Cells in refractory B-Cell lymphomas

New England Journal of Medicine

Volumn 377, Issue 26, 2017, Pages 2545-2554

  Schuster, Stephen J ^a   Svoboda, Jakub ^a   Chong, Elise A ^a   Nasta, Sunita D ^a   Mato, Anthony R ^a   Anak, Özlem ^c   Brogdon, Jennifer L ^d   Pruteanu Malinici, Iulian ^d   Bhoj, Vijay ^b   Landsburg, Daniel ^a   Wasik, Mariusz ^b   Levine, Bruce L ^b   Lacey, Simon F ^b   Melenhorst, Jan J ^b   Porter, David L ^a   June, Carl H ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; BIOLOGICAL MARKER; CD19 ANTIGEN; CTL019 CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; BONE MARROW; BRAIN DISEASE; CANCER REGRESSION; CELL THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; CONFUSION; CYTOKINE RELEASE SYNDROME; DELIRIUM; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TREMOR; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; MIDDLE AGED; MORTALITY; REMISSION; SURVIVAL ANALYSIS;

ADULT; AGED; ANTIGENS, CD19; B-LYMPHOCYTES; BIOMARKERS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; REMISSION INDUCTION; SURVIVAL ANALYSIS; T-LYMPHOCYTES;

EID: 85040171486     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708566     Document Type: Article

References (27)

1. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.
2. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
3. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90.
4. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: The Stanford University experience. Blood 2013; 122: 981-7.
5. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. J Clin Oncol 2015; 33: 2516-22.
6. Salles G, Schuster SJ, de Vos S, et al. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study. Haematologica 2017; 102(4): E156-e159.
7. Aliqopa (copanlisib). Whippany, NJ: Bayer HealthCare Pharmaceuticals, September 2017 (package insert) (https:/ / www .accessdata .fda .gov/ drugsatfda -docs/ label/ 2017/ 209936s000lbl .pdf).
8. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-18.
9. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-17.
10. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33.
11. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-9.
12. Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016; 8: 355ra116.
13. Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 2017; 25: 2245-53.
14. Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T-cell therapy in refractory aggressive lymphoma. Mol Ther 2017; 25: 285-95.
15. Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor Tcells are associated with high serum interleukin-15 levels. J Clin Oncol 2017; 35: 1803-13.
16. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
17. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-64.
18. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-53.
19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-86.
20. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds Meeting. J Clin Oncol 1989; 7: 1630-36.
21. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
22. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117: 2319-31.
23. Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7: 303ra139.
24. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-20.
25. Crump M, Neelapu S, Farooq U, et al. Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study. J Clin Oncol 2016; 34: Suppl: 7516. abstract.
26. Schuster SJ, Bishop MR, Tam C, et al. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - an interim analysis. Hematol Oncol 2017; 35: Suppl 2: 27. abstract.
27. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel (axi-cel; KTEC19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): Primary results of the pivotal trial ZUMA-1. Hematol Oncol 2017; 35: Suppl 2: 28. abstract.